Drugs / DNK333
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01287325 | Sep 2003 → Apr 2004 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01033097 | Nov 2009 → Jul 2011 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00394173 | Sep 2006 → Oct 2007 | irritable bowel syndrome | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00699166 | Apr 2004 → Sep 2005 | irritable bowel syndrome | Novartis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNK333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00394173 ↗ |
| Action | Inhibit | “DNK333, a novel neurokinin antagonist” PMID 21507028 ↗ Apr 20111“Neurokinin 1 receptor antagonist” CHEMBL105060 ↗ |
| Modality | Small molecule | — CHEMBL105060 ↗ |
| Route | Oral | “DNK333 25mg b.i.d. given orally for 4 weeks” NCT00394173 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL105060 ↗ |